XRCC2 and lung carcinoma: Consistent with this, the combined treatment effectively decreased the levels of HR pathway genes, including BRCA1, BRCA2, RAD51, RAD54L, BRIP1, BARD1, XRCC2 and RBBP8 in lung cancer cells, compared to either drug treatment (Figure 6B).